Incivek
Vertex ditches its once-stellar hep C drug
August 14, 2014Sales and Marketing Gilead, Incivek, Vertex, hep C, sovaldi
Vertex will stop selling its once-blockbuster hepatitis C drug in the US this autumn after being crushed by new therapies. …
Gilead price lambasted by US health insurers
May 21, 2014Medical Communications, Sales and Marketing Gilead, Incivek, Victrelis, hepatitis C, sovaldi
Gilead’s new hepatitis C pill Sovaldi is coming under more pressure in the US as health insurers hit out at …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Janssen launches Incivo in the UK
October 10, 2011Sales and Marketing Incivek, Incivo
Janssen’s new hepatitis C treatment Incivo has been launched in the UK, one of two new drugs set to advance …
J&J’s hep C drug Incivo approved in Europe
September 22, 2011Sales and Marketing Incivek, Incivo, Victrelis
J&J’s potential blockbuster hepatitis C treatment Incivo has been approved in Europe. Incivo (telaprevir) was approved in combination with peginterferon …
Hep C drug Victrelis gains EU approval
July 20, 2011Sales and Marketing Incivek, Victrelis, hepatitis C
Merck Sharp & Dohme’s Victrelis, one of two major new hepatitis C drugs, has gained final approval in Europe. Victrelis …
Hepatitis C rivals go head to head
July 19, 2011Sales and Marketing Incivek, Incivo, Victrelis, boceprevir, hepatitis C, telaprevir
The field of hepatitis C treatment has two new groundbreaking medicines to treat the condition.Merck’s Victrelis (boceprevir) and Johnson & …
J&J and Vertex’s hep C drug Incivek approved by FDA
May 24, 2011Sales and Marketing FDA, Incivek, Johnson & Johnson, Vertex, hepatitis C, telaprevir
The FDA has approved Johnson & Johnson/Vertex’s new oral hepatitis C drug Incivek. Incivek (telaprevir), a protease inhibitor, is now …
Latest content
